Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 1, 2010, Pages 1-12

  Sharkey, Robert M ^a   Rossi, Edmund A ^b   Chang, Chien Hsing ^c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

Antibody therapy; Bispecific antibodies; Molecular imaging; Non Hodgkin's lymphoma; Pretargeting; Radioimmunotherapy; Recombinant antibodies

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY; CD20 ANTIBODY; EPRATUZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RADIOISOTOPE; VELTUZUMAB; ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; CANCER DIAGNOSIS; CANCER THERAPY; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; CHEMISTRY; HUMAN; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; MOLECULAR IMAGING; NEOPLASMS;

EID: 77649291920     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0690     Document Type: Review

References (125)

1. Pressman D. The zone of localization of antibodies: The specific localization of antibodies to rat kidney. Cancer 1949;2:697.
2. Pressman D, Korngold L. The in vivo localization of anti-Wagner- osteogenic-sarcoma antibodies. Cancer 1953;6:619.
3. Bale WF, Spar IL, Goodland RL. Experimental radiation therapy of tumors with I-131-carrying antibodies to fibrin. Cancer Res 1960;20:1488.
4. Goldenberg DM, Hansen HJ. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science 1972;175:1117.
5. Primus FJ, Wang RH, Goldenberg DM, et al. Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res 1973;33:2977.
6. Goldenberg DM, Preston DF, Primus FJ, et al. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res 1974;34:1.
7. Primus FJ, Macdonald R, Goldenberg DM, et al. Localization of GW-39 human tumors in hamsters by affinitypurified antibody to carcinoembryonic antigen. Cancer Res 1977;37:1544.
8. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. NEJM 1978;298:1384.
9. Pettit WA, DeLand FH, Bennett SJ, et al. Radiolabeling of affinity-purified goat anti-carcinoembryonic antigen immunoglobulin G with technetium-99m. Cancer Res 1980;40: 3043.
10. Eckelman WC, Paik CH, Reba RC. Radiolabeling of antibodies. Cancer Res 1980;40:3036.
11. Epenetos AA, Nimmon CC, Arklie J, et al. Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br J Cancer 1982;46:1.
12. Baldwin RW, Pimm MV. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Metastasis Rev 1983;2:89.
13. Hnatowich DJ, Layne WW, Childs RL, et al. Radioactive labeling of antibody: A simple and efficient method. Science 1983;220:613.
14. Goodwin DA, Meares CF, McCall MJ, et al. Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. J Nucl Med 1985;26:493.
15. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49:2639.
16. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Semin Nucl Med 1990;20:80.
17. Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Int J Rad Appl Instrum B 1991;18:369.
18. Griffiths GL, Goldenberg DM, Jones AL, et al. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjug Chem 1992;3:91.
19. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473.
20. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 1988; 85:5879.
21. Johnson S, Bird RE. Construction of single-chain Fv derivatives monoclonal antibodies and their production in Escherichia coli Meth Enzymol 1991;203:88.
22. Pack P, Pluckthun A. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli Biochemistry 1992;31:1579.
23. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402.
24. Pack P, Kujau M, Schroeckh V, et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli Biotechnology (NY) 1993;11:1271.
25. Sharkey RM, Goldenberg DM. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Invest Drugs 2008;9:1302.
26. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64:2853.
27. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Exp Opin Biol Ther 2005; 5:111.
28. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nano-bodies through albumin binding: Taking advantage of modular nanobody technology. Mol Cancer Ther 2008; 7:2288.
29. Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009;284:3273.
30. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009; 198:157.
31. Nord K, Gunneriusson E, Ringdahl J, et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772.
32. Skerra A. "Anticalins": a new class of engineered ligand-binding proteins with antibody-like properties. J Biotechnol 2001;74:257.
33. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;13:245.
34. Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov Today 2008;13:695.
35. Skerra A. Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 2008; 275:2677.
36. Nygren PA, Skerra A. Binding proteins from alternative scaffolds. J Immunol Meth 2004;290:3.
37. Xu L, Aha P, Gu K, et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 2002;9:933.
38. Ronnmark J, Hansson M, Nguyen T, et al. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli J Immunol Meth 2002;261:199.
39. Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22:575.
40. Tran TA, Rosik D, Abrahmse ́n L, et al. Design, synthesis, and biological evaluation of a multifunctional HER2-specific affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 2009;36:1864.
41. Tolmachev V, Orlova A, Nilsson FY, et al. Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy. Exp Opin Biol Ther 2007;7:555.
42. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2-binding affibody molecule. Cancer Res 2006;66:4339.
43. Yan AC, Levy M. Aptamers and aptamer-targeted delivery. RNA Biol 2009;6:316.
44. Tavitian B, Duconge F, Boisgard R, et al. In vivo imaging of oligonucleotidic aptamers. Meth Mol Biol 2009;535:241.
45. Bardou C, Borie C, Bickle M, et al. Peptide aptamers for small-molecule drug discovery. Meth Mol Biol 2009;535:373.
46. Balhorn R, Hok S, Burke PA, et al. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res 2007;13:5621s.
47. DeNardo GL, Hok S, Van Natarajan A, et al. Characteristics of dimeric (bis) bidentate selective high-affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol 2007;31:729.
48. DeNardo GL, Natarajan A, Hok S, et al. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med 2007;48:1338.
49. DeNardo GL, Mirick GR, Hok S, et al. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol 2009;34:511.
50. Goldenberg DM, Gaffar SA, Bennett SJ, et al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981;41:4354.
51. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987;47:5672.
52. Sharkey RM, Motta-Hennessy C, Gansow OA, et al. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int J Cancer 1990;46:79.
53. 123Ior 99mTc. Cancer Res 1990;50:909s.
54. Griffiths GL, Goldenberg DM, Diril H, et al. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer 1994;73:761.
55. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179.
56. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies. Bioconjug Chem 1998; 9:773.
57. Juweid M, Sharkey RM, Swayne LC, et al. Pharmacokinetics, dosimetry, and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 1998;39:34.
58. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999;85:1828.
59. 18F-FDG PET in oncology. J Nucl Med 2008;49:480.
60. 213Bi-versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 1999;59:2635.
61. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 1998;77: 787.
62. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmuno-therapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035.
63. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
64. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 2004;19:378.
65. 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46 (Suppl 1):99S.
66. 3-octreotate. J Nucl Med 2005;46 (Suppl 1):83S.
67. 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847.
68. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 2008;60:1407.
69. Buchegger F, Press OW, Delaloye AB, et al. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 2008;13:657.
70. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622.
71. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: Modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006;1: 2048.
72. Kenanova V, Olafsen T, Williams LE, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: Optimal pharmacokinetics for therapy. Cancer Res 2007;67:718.
73. DeNardo GL, Kroger LA, Meares CF, et al. Comparison of 1,4,7,10-tetraazacyclododecane-N,N′,NN000-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido) benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin Cancer Res 1998;4:2483.
74. Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug Chem 1998; 9:618.
75. Peterson JJ, Meares CF. Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjug Chem 1999;10:553.
76. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects, and limitations. Eur J Nucl Med 1998;25:201.
77. 111In-octreo-tide in mice and rats. J Nucl Med 2006;47:528.
78. Vegt E, van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008;49:1506.
79. 111In-DOTATOC in rats: Influence of inhibitors of the organic ion transport and diuretics. Eur J Nucl Med Mol Imaging 2007;34:2129.
80. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987;28: 1604.
81. Chen JQ, Strand SE, Tennvall J, et al. Extracorporeal immunoadsorption compared to avidin chase: Enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med 1997;38:1934.
82. 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm 2005;20:457.
83. Reardon DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;316:265.
84. Abdel-Nabi HH, Schwartz AN, Goldfogel G, et al. Color-ectal tumors: Scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. Radiology 1988;166: 747.
85. Abdel-Nabi HH, Schwartz AN, Higano CS, et al. Colorectal carcinoma: Detection with indium-111 anticarcinoembryonic-antigen monoclonal antibody ZCE-025. Radiology 1987;164: 617.
86. Halpern SE, Haindl W, Beauregard J, et al. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: Kinetics, biodistribution, and tumor detection. Radiology 1988;168:529.
87. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991;51: 6650.
88. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358.
89. Moffat FL, Jr., Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab0 antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14:2295.
90. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879.
91. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802.
92. Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmuno-therapy. Cancer Biother Radiopharm 1999;14:153.
93. Gautherot E, Bouhou J, Le Doussal JM, et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer 1997; 80:2618.
94. 131I- labeled bivalent hapten. J Nucl Med 2000;41:480.
95. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin's lymphoma. J Nucl Med 2009;50:444.
96. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282.
97. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 2008;111:2261.
98. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmuno-therapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535.
99. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother 1994;16:158.
100. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 1997;8:595.
101. 188Re-labeled peptide. Bioconjug Chem 2000;11: 842.
102. Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 2002;13:1054.
103. Hosono M, Hosono MN, Kraeber-Bodere F, et al. Two-step targeting and dosimetry for small-cell lung cancer xeno-graft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med 1999;40: 1216.
104. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 1997;8:526.
105. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354.
106. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s.
107. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol 1990;27:995.
108. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003;9:3886S.
109. Rossi EA, Chang CH, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005;11:7122s.
110. Schoonjans R, Willems A, Schoonooghe S, et al. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000;165:7050.
111. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock-and-lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841.
112. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: Opposites attract. FEBS Lett 2005;579:3264.
113. Wong W, Scott JD. AKAP signalling complexes: Focal points in space and time. Nat Rev Mol Cell Biol 2004;5:959.
114. Sharkey RM, Karacay H, Vallabhajosula S, et al. Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497.
115. 18F radiolabeling for PET. J Nucl Med 2009;50: 991.
116. 68Gaand 18F-labeled hapten-peptide in mice with human tumor xenografts. Mol Cancer Ther 2010; in press.
117. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008;68:4819.
118. Chang CH, Rossi EA, Goldenberg DM. The dock-and-lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13:5586s.
119. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158.
120. Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res 2008;68:8384.
121. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062.
122. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704.
123. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Exp Rev Anticancer Ther 2006;6:1341.
124. Rossi EA, Goldenberg DM, Cardillo TM, et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009;113:6161.
125. Rossi EA, Goldenberg DM, Cardillo TM, et al. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864.